EcoDrugPlus

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSTRUG00000001926
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSTRUG00000014808
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSTRUG00000007422
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSTRUG00000013788
Gene Symbol: ADAM17
3 Cross references
208 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSTRUG00000010983
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSTRUG00000006087
Gene Symbol: ADRM1
3 Cross references
191 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSTRUG00000013476
Gene Symbol: AKT1
4 Cross references
195 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSTRUG00000010044
Gene Symbol: ALK
2 Cross references
193 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSTRUG00000009219
Gene Symbol: ABCC9
3 Cross references
231 Possible Orthologues:

Atp-Sensitive Inward Rectifier Potassium Channel 11

Ensembl ID : ENSTRUG00000028034
Gene Symbol: LOC101065431
3 Cross references
187 Possible Orthologues:

Atp-Sensitive Inward Rectifier Potassium Channel 11-Like

Ensembl ID : ENSTRUG00000007184
Gene Symbol: LOC101065431
3 Cross references
187 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1a, Tandem Duplicate 2

Ensembl ID : ENSTRUG00000012850
Gene Symbol: ATP1A1A.2
1 Cross references
181 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).